Dec 11, 2025
By STEVEN ZECOLA
Recursion Prescription drugs introduced outcomes in the present day for one its AI-discovered therapies. I used to be happy to see the massive, sustained discount in polyps attributable to its therapy for Familial Adenomatous Polyposis. Recursions’ oral treatment might be seen by the standard scientific and regulatory group as “promising”.
However, I used to be upset to not see/hear any reference to the financial savings of the price to society from this therapy and a obscure reference to working with the FDA in 1H2026. Fairly frankly, the urgency gave the impression to be missing.
At the moment, treating FAP is an costly, lifelong endeavor for the 50,000+ survivors. Early detection methods price $10k+ and late detection $37k+. The price to treating metastatic colorectal most cancers (for which FAP predisposes) will be extraordinarily excessive, as much as $300,000. Total, the price to society from FAP simply exceeds $1 billion per 12 months, or greater than $15 billion on a gift worth foundation.
This treatment shouldn’t be topic to any additional regulatory delay. There may be sufficient data now on efficacy and security to have Recursion extra ahead with a broad software of this therapy, whereas persevering with take a look at dosage ranges and stratifying the affected person inhabitants. The choice is extra unnecessary price and struggling.
Steve Zecola offered his net software and internet hosting enterprise when he was identified with Parkinson’s illness twenty three years in the past. Since then, he has run a consulting follow, taught in graduate enterprise college, and exercised extensively
